Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer

Our phase II trial (FABRIC study) failed to verify the efficacy of gemcitabine plus oxaliplatin (GEMOX) in patients with pancreatic ductal adenocarcinoma (PDAC) with a familial or personal history of pancreatic, breast, ovarian or prostate cancer, which suggested that a family and personal history m...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Japanese journal of clinical oncology 2022-10, Vol.52 (10), p.1105-1114
Hauptverfasser:	Terashima, Takeshi, Morizane, Chigusa, Ushiama, Mineko, Shiba, Satoshi, Takahashi, Hideaki, Ikeda, Masafumi, Mizuno, Nobumasa, Tsuji, Kunihiro, Yasui, Kohichiroh, Azemoto, Nobuaki, Satake, Hironaga, Nomura, Shogo, Yachida, Shinichi, Sugano, Kokichi, Furuse, Junji
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - genetics Genetic Predisposition to Disease Germ Cells Germ-Line Mutation Humans Male Oxaliplatin - therapeutic use Pancreatic Neoplasms Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Pancreatic Neoplasms - pathology Prostatic Neoplasms
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!